The National Institutes of Health Clinical Center in Bethesda, MD, recently announced a Phase 1 clinical trial of a novel influenza vaccine that has begun inoculating healthy adult volunteers.
This innovative study will evaluate the safety of the whole-virus BPL-1357 vaccine candidate’s ability to prompt immune responses.
BPL-1357 was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID).
Universal Flu Shot Launches Early Clinical Study
Universal Flu Shot Launches Early Clinical Study
The National Institutes of Health Clinical Center in Bethesda, MD, recently announced a Phase 1 clinical trial of a novel influenza vaccine that has begun inoculating healthy adult volunteers.
This innovative study will evaluate the safety of the whole-virus BPL-1357 vaccine candidate’s ability to prompt immune responses.
BPL-1357 was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID).
U.S. Orders 105 Million More Pfizer Shots for Fall Booster Campaign
Both Pfizer and Moderna have reported positive results with updated vaccines that target the omicron variant
Two Doses of BNT162b2 Moderately Effective for 5- to 11-Year-Olds
Moderate effectiveness against documented infection and symptomatic COVID-19 for those vaccinated on or after Nov. 23, 2021
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
FDA Tells Vaccine Makers to Update Boosters to Target Omicron Subvariants
Pfizer and Moderna are expected to start producing reformulated doses this summer
Fauci Has ‘Rebound’ COVID After Paxlovid Treatment
However, director of the NIAID says drug kept him out of the hospital